Please provide your email address to receive an email when new articles are posted on . Atezolizumab monotherapy induced objective responses in more than one-third of patients. No treatment-related ...

Aug 7, 2022 Aug 7, 2022 Updated Aug 7, 2022 LOUISVILLE, Ky. (WDRB) -- “To always have hope no matter what comes up, you can either choose fear or hope, and I feel like hope is always the best option.” ...

A clinical trial has resulted in the first approval of a treatment for advanced alveolar soft part sarcoma (ASPS). The immunotherapy drug atezolizumab (Tecentriq) was recently approved by the U.S.

Alveolar soft part sarcoma (ASPS) remains one of the rare and enigmatic soft tissue malignancies, principally affecting adolescents and young adults. Despite its low incidence, recent research has ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved atezolizumab for adults and children aged 2 years or older with unresectable or metastatic ...

Self-Reported Conflicts of Interest of Authors, Trial Sponsorship, and the Interpretation of Editorials and Related Phase III Trials in Oncology Alveolar soft part sarcoma (ASPS) is a rare, highly ...

A clinical trial led by the National Cancer Institute (NCI), part of the National Institutes of Health, has resulted in the first approval of a treatment for advanced alveolar soft part sarcoma (ASPS) ...

Although all authors completed the disclosure declaration, the following author(s) and/or an author's immediate family member(s) indicated a financial or other interest that is relevant to the subject ...

For most types of STS and for earlier stages of sarcoma, the treatment is usually similar. People may have surgery alone, or radiation therapy or chemotherapy in addition to surgery. Treatment may ...

Credit: Thinkstock. The approval was based on data from a phase 2 study that included 49 patients with unresectable or metastatic ASPS. The Food and Drug Administration (FDA) has approved Tecentriq ...

image: Left frame: Normally, tumor cells (purple) evade the immune system’s T cells (pink) by expressing a checkpoint protein known as PD-L1. Right frame: Atezolizumab (Tecentriq) binds to PD-L1 and ...